Integrative drug repositioning identifies FDA-approved inhibitors of HSP90AA1 with therapeutic potential in colorectal cancer
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Xuan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dongguan Key Laboratory of Computer-Aided Drug Design, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523710, China; …. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Colorectal Neoplasms, Antineoplastic Agents, Drug Repositioning. Die Arbeit nennt 80 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a leading cause of cancer mortality, with treatment efficacy limited by tumor heterogeneity and chemotherapy resistance. Drug repositioning can accelerate discovery using FDA-approved agents. Here, we introduce a multi-omics repositioning framework integrating bulk and single-cell data with network pharmacology, structural modeling, and validation and apply it for the first time in CRC. Bulk RNA-seq identified 3480 upregulated and 3816 downregulated genes in TCGA-COADREAD, and 602 upregulated and 744 downregulated in GSE103512. Single-cell RNA-seq revealed 1227 upregulated and 728 downregulated in GSE231559, and 1628 upregulated and 850 downregulated in GSE144735. Integration with cMap and ASGARD yielded 20 candidates; four FDA-approved drugs (rifapentine, danazol, tolbutamide, and triamcinolone) had not been linked to CRC. DepMap PRISM data supported inhibitory activity. Docking and 200 ns molecular dynamics showed stable binding of all four in the HSP90α ATP-binding pocket, with hydrogen bonding and favorable MM/GBSA free energies (-30.59 kcal/mol for danazol to -37.37 kcal/mol for rifapentine; reference NVP-AUY922 -47.99 kcal/mol). Independent triplicate simulations of the reference and top-ranked candidate complexes confirmed the statistical reliability and reproducibility of these structural and energetic descriptors (reference ΔGtotal = -47.90 ± 0.08 kcal/mol). Direct binding of all four compounds to HSP90α was further confirmed by surface plasmon resonance. In vitro, the drugs suppressed proliferation and induced apoptosis in HCT116, LoVo, and HCT-15 cells, with IC₅₀ values of 2.60-13.15 μM. These results identify unreported HSP90AA1 inhibitors in CRC and establish a generalizable repositioning framework.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dongguan Key Laboratory of Computer-Aided Drug Design, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523710, China; Guangdong Medical University Key Laboratory of Big Data Mining and Pre…
- Dongguan Key Laboratory of Computer-Aided Drug Design, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523710, China.
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau 999078, China. Electronic address: defangouyang@umac.mo.
Zitieren
APA
Li, X., Xu, S., Waqas, M., Zhang, H., Ouyang, D., & Huang, Z. (2026). Integrative drug repositioning identifies FDA-approved inhibitors of HSP90AA1 with therapeutic potential in colorectal cancer. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110262
Vancouver
Li X, Xu S, Waqas M, Zhang H, Ouyang D, Huang Z. Integrative drug repositioning identifies FDA-approved inhibitors of HSP90AA1 with therapeutic potential in colorectal cancer. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110262
BibTeX
@article{Li2026,
author = {Li, Xuan and Xu, Shaofen and Waqas, Muhammad and Zhang, Haoke and Ouyang, Defang and Huang, Zunnan},
title = {Integrative drug repositioning identifies FDA-approved inhibitors of HSP90AA1 with therapeutic potential in colorectal cancer},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110262}
}
EUVIMED